Antibodies against nephronectin ameliorate anti-type II collagen-induced arthritis in mice

Shigeyuki Kon¹, Machiko Honda¹, Kiyoshi Ishikawa², Masahiro Maeda² and Tatsuya Segawa²

¹ Department of Molecular Immunology, Faculty of Pharmaceutical Sciences, Fukuyama University, Japan
² Immuno-Biological Laboratories, Fujioka, Japan

Keywords
antibody; anti-type II collagen-induced arthritis; autoimmune diseases; ELISA; nephronectin

Correspondence
S. Kon, Department of Molecular Immunology, Faculty of Pharmaceutical Sciences, Fukuyama University, 985, Sanzo, Higashimura-cho, Fukuyama 729-0292, Japan
Fax: +81 84 736 2024
Tel: +81 84 736 2112
E-mail: kon@fukuyama-u.ac.jp

(Received 27 August 2019, revised 25 October 2019, accepted 7 November 2019)
doi:10.1002/2211-5463.12758

The extracellular matrix protein nephronectin (Npnt) is known to be critical for kidney development, but its function in inflammatory diseases is unknown. Here, we developed a new enzyme-linked immunosorbent assay system to detect Npnt in various autoimmune diseases, which revealed that plasma Npnt levels are increased in various mouse autoimmune models. We also report that antibodies against the αβ1 integrin-binding site of Npnt protect mice from anti-type II collagen-induced arthritis, suggesting that Npnt may be a potential therapeutic target molecule for the prevention of autoimmune arthritis.

The extracellular matrix (ECM) primarily functions to support the intercellular space; however, recent studies suggest that the ECM regulates various cellular functions including cell differentiation, cell growth, survival, adhesion, and migration by mediating integrin receptors [1–3]. A wide variety of ECM proteins have the same primary sequence motif, a tripeptide, Arg-Gly-Asp (RGD) motif for integrin binding [4]. The expression of some ECM components is increased during autoimmune diseases [5,6]. For example, we previously reported that osteopontin (OPN), an ECM protein containing an RGD motif, is highly expressed in inflammatory diseases and critically involved in autoimmune diseases, including collagen antibody-induced arthritis (CAIA) [7,8] and concanavalin A (ConA)-induced hepatitis [9]. Therefore, aberrant ECM expression facilitates disease development.

An ECM protein, nephronectin (Npnt), is expressed in kidneys and hair follicles [10,11]. Npnt consists of five epidermal growth factor (EGF)-like repeats in N-terminal region, a linker segment containing an RGD integrin-binding site, and a meprin/A5-protein/PTPmu (MAM) domain in C-terminal region [10]. The RGD sequence in Npnt is critical for binding to its receptor, αβ1 integrin, and the interaction is critically involved in kidney development [10,12]. EGF-like repeats and MAM domains are responsible for binding to chondroitin sulfate and heparan sulfate, respectively [13]. The involvement of Npnt in diseases has been reported, particularly kidney diseases [14–17].
and chronic hepatitis [18], and tumor progression [19–21].

We performed real-time PCR to evaluate Npnt expression in tissues and found that Npnt expression was high in the spleen. Therefore, we hypothesize that Npnt may play an important role in autoimmune diseases. To test this hypothesis, we developed an enzyme-linked immunosorbent assay (ELISA) system for quantification of Npnt protein expression levels and generated an antibody against the α8β1 integrin-binding site. In the present study, we show the expression and functional importance of Npnt in autoimmune diseases.

Materials and methods

Reagents and cell lines

Mouse nephronectin (Npnt) protein [called Npnt (R&D) protein in this study] was from R&D systems (Minneapolis, MN, USA). RD cells (derived from a human rhabdomyosarcoma), A549 cells (derived from human lung adenocarcinoma), HepG2 (derived from human hepatocellular carcinoma), LN-229 cells (derived from human glioblastoma), B16 cells (derived from mouse skin melanoma), NIH3T3 cells, MEF cells, L929 cells (derived from mouse fibroblast), NIH3T3 cells, MEF cells, L929 cells (derived from mouse fibroblast) were cultured in DMEM containing 10% fetal bovine serum (FBS). Raji cells (derived from human Burkitt’s lymphoma), Jurkat cells (derived from human T-cell leukemia), U937 cells (derived from human histiocytic lymphoma), HL60 cells (derived from human acute promyelocytic leukemia), Ehrlich cells (derived from mouse Ehrlich-Lettre ascites carcinoma), X63 cells (derived from mouse myeloma) were cultured in RPMI containing 10% FBS.

Animals

Mice and rats were kept under specific pathogen-free conditions and provided food and water ad libitum. Every effort was made to minimize suffering during injections, and all surgery was performed on humanely sacrificed animals. All animal experiments were performed in accordance with the guidelines of the Bioscience Committee of and were approved by the Animal Care and Use Committee of Immuno-biological Laboratories.

Specific pathogen-free BALB/c mice, C57BL/6, and SD rats were purchased from Japan SLC (Hamamatsu, Japan).

Real-time PCR

Total RNA from healthy mouse tissues, arthritic joints, and synovial cells was extracted with TRIzol (Thermo Fisher, Hanover Park, IL, USA). First-strand cDNA was generated with a first-strand cDNA synthesis kit (TOYOBO, Osaka, Japan). For human Npnt expression in human tissues, a human multiple tissue cDNA panel was used (Takara, Kusatsu, Japan). The specific primers used are shown in Table 1. The expression level of mRNA was calculated using the calibration curve method using LIGHTCYCLER software version 3 (Roche Diagnostics, Indianapolis, IN, USA). Data were standardized to G3PDH.

Npnt preparation

The human Npnt complementary DNAs (cDNAs) were PCR-amplified from A549 cells. Primer sets for cloning of Npnt are shown in Table 2. The amplified product was cloned into a pM-secSUMOstar vector (LifeSensors, Malvern, PA, USA), which contains a His-tag and SUMO tag at the 5’ end of the cloning sites for purification and enhancing expression and solubility. The cDNAs encoding domain of human Npnt was subcloned into pM-secSUMOstar in-frame with a His-tag and SUMO tag. EGF-like repeats, Linker segment, and MAM domain were amplified by PCR using primer sets described in Table 2. The Npnt expression plasmids after nucleotide sequence confirmation were transfected into 293 cells with Lipofectamine 2000 (Thermo Fisher). His-SUMO-tagged human Npnt was purified using TALON Resin (Takara) following the manufacturer’s protocol.

Production and purification of polyclonal and monoclonal antibodies against Npnt

Synthetic peptides used for immunization were as follows: Npnt3 peptide FKGEKRRGHTGEIGLDDVSL and NPNT-FD peptide PQKPRGDVFIPRQPTNDLFIEIERR, which correspond to common amino acid sequences in human and mouse Npnt, and the functional domain of mouse Npnt for α8β1 integrin, respectively. These peptides were used to immunize rabbits after coupling with thyroglobulin. The immunoglobulin (Ig) G fraction was obtained from a sepharose column coupled with the synthetic peptide used as the immunogen.

Generation of monoclonal antibodies against Npnt was as follows. SD rats were subcutaneously immunized with mouse Npnt protein mixed with Freund’s complete

Table 1. Real-time PCR primer sequences.

| Gene            | Sequence of primers                        |
|-----------------|--------------------------------------------|
| Human Npnt      | 5'-AAATGAGTCGTGGGCTGTAAGG-3'               |
|                 | 5'-GCCATGAGGAGCTTTGATGAG-3'                |
| Mouse Npnt      | 5'-CTCTGAGATGAGCATT-3'                     |
| Human α8 integrin| 5'-CTCTGAGATGAGCATT-3'                     |
| Mouse α8 integrin| 5'-GAATGATGAGCATT-3'                      |
adjuvant (Becton Dickinson, Sparks, MD, USA) and immunized with mouse Npnt protein mixed with Freund’s incomplete adjuvant (Becton Dickinson) (days 7, 14, and 21). Spleen cells were harvested and fused with X63-Ag8-653 cells in the presence of polyethylene glycol (Roche Diagnostics, Indianapolis, IN, USA). Hybridomas were screened for production of antibody specifically reactive to immobilized mouse Npnt used for the immunization, and one IgG1 clone (20D1a) from the mouse Npnt protein was obtained.

Establishing the Npnt sandwich ELISA system

About 5 \( \mu g \cdot mL^{-1} \) of rabbit anti-Npnt3 antibody was used as a capture antibody, and 2 ng \( \cdot mL^{-1} \) of 20D1 conjugated with HRP by using Peroxidase labeling kit according to the manufacturer’s instructions (DOJINDO, Kumamoto, Japan) was used as the detection antibody. Purified mouse Npnt (R&D) protein was used as the standard. 100 \( \mu L \) of the diluted sample was applied to each well of the antibody-coated plate and incubated for 1 h at 37 °C. The wells were washed three times with PBS-T [PBS containing 0.05% (v/v) Tween-20], and then, 100 \( \mu L \) of detection antibody was added and incubated for 30 min at 4 °C. Each well was washed with PBS-T and incubated with 100 \( \mu L \) of 3,3',5,5'-tetramethyl benzidine (TMB) (Sigma-Aldrich, St Louis, MO, USA) for 30 min, and then, 100 \( \mu L \) of 1 m sulfuric acid was added. Plates were read at a wavelength of 450 nm by an immunoreader (Thermo Fisher).

Direct ELISA

Mouse Npnt (R&D), fibronectin (Sigma-Aldrich, St Louis, MO, USA), GRGDS peptide-coupled with BSA were coated onto 96-well plate at a concentration of 1 \( \mu g \cdot mL^{-1} \) at 37 °C for 1 h, then blocked with 0.1% BSA in PBS containing 0.05% NaN\(_3\) at 37 °C for at least 1 h. The plates were washed two times with PBS-T and incubated with anti-Npnt-FD mAb at various concentrations at 37 °C for 1 h. After a further three washes, 1 : 5000 dilution of HRP-conjugated anti-mouse IgG antibody (Jackson Immuno Research, West Grove, PA, USA) was added to each well at room temperature for 30 min. Bound protein was quantified by a colorimetric assay using TMB as a substrate for 15 min at room temperature. Plates were read at a wavelength of 450 nm by an immunoreader.

Cell adhesion assay

The 96-well plates were precoated with hNpnt, mNpnt (R&D), NPNT-FD synthetic peptides, fibronectin, or vitronectin (2 \( \mu g\cdot mL^{-1} \)) at 37 °C for 1 h, followed by treatment with 0.5% BSA in PBS for 1 h at room temperature. Cells in the presence or absence of various concentrations of antibody were suspended in DMEM containing 0.25% BSA, and 200 \( \mu L \) of cell suspension (at a cell density of 5 \( \times 10^4 \) cells/well) was applied to 96-well plates and incubated for 1 h at 37 °C. The medium was removed from the plates, and all wells were washed twice. The adherent cells were fixed and stained with 0.5% crystal violet in 20% methanol for 30 min. All wells were rinsed three times with water, and adherent cells were then lysed with 20% acetic acid. The resulting supernatants from each well were analyzed by an immunoreader, and the absorbance at 595 nm was measured to determine the relative number of cells adhered to wells.

Fractionation of synovial tissues

Hind limbs were surgically removed from the ankle joint, followed by surgical separation of the dermal, subcutaneous, tendinous, and muscle tissues from joints. The remaining soft tissues were removed from the bones and homogenized roughly with dissecting scissors. Homogenates were washed once with culture medium and treated with 3 \( mg\cdot mL^{-1} \) type II collagenase (Worthington Biochemical, Freehold, NJ, USA) by vigorous stirring. After washing, synovial cells were fractionated into TLR-4+ or TLR-4− fractions using MACS (Miltenyi Biotec, Auburn, CA, USA). The TLR-4+ fraction was considered macrophages and the TLR-4− fraction was cultured overnight, and adherent cells were used as fibroblasts.

Arthritis model

Arthritis was induced using an arthritogenic 5-clone monoclonal antibody cocktail kit (Chondrex Inc., Redmond, WA, USA).

| Table 2. Primer sequences for cloning of Npnt. |

| Gene          | Sequence of primers                                      |
|---------------|---------------------------------------------------------|
| Human Npnt    | 5'-TATTGGAGGCTCATCCGAACAGATTTGGAGGTGGCAGCTGAGCAGTG3'    |
|               | 5'-ATGCTCCAGTCTGACGATTCTGTCCACTAACACAGAGTGACGCC3'      |
| EGF-like repeats | 5'-TATTGGAGGCTCATCCGAACAGATTTGGAGGTGGCAGCTGAGCAGTG3'    |
| Linker segment | 5'-ATGCTCCAGTCTGACGATTCTGTCCACTAACACAGAGTGACGCC3'      |
| MAM domain    | 5'-TATTGGAGGCTCATCCGAACAGATTTGGAGGTGGCAGCTGAGCAGTG3'    |
|               | 5'-ATGCTCCAGTCTGACGATTCTGTCCACTAACACAGAGTGACGCC3'      |
WA, USA) following the manufacturer’s protocol. Briefly, 7-week-old female BALB/c mice were injected intravenously with a mixture of five anti-type II collagen monoclonal antibodies (2 mg each) on day -3, followed by an intraperitoneal injection of 50 µg of lipopolysaccharide (LPS) (0111:B4) on day 0. About 400 µg anti-Npnt-FD antibody or control rabbit IgG was administered intraperitoneally at doses of 400 µg per mouse on days -4 and 0. The clinical severity of arthritis was graded up to 9 days after LPS administration in each of the four paws on a 0–4 scale. The disease severity was recorded for each limb as follows: 0, normal; 1, focal slight swelling and/or redness in one digit; 2, moderate swelling and erythema of two digits; 3, marked swelling and erythema of the limb; and 4, maximal swelling, erythema, deformity, and/or ankylosis. Mice were scored in a double-blind manner. Mice were sacrificed, and then, joint sections were stained with hematoxylin and eosin (HE) and fast green/safranin-O for immunohistochemical evaluation.

**Induction of concanavalin A-induced hepatitis and experimental autoimmune encephalomyelitis**

For induction of ConA-hepatitis, BALB/c mice were injected intravenously with 15 mg ConA (Sigma-Aldrich) per kilogram of body weight, dissolved in pyrogen-free PBS.

For induction of experimental autoimmune encephalomyelitis (EAE), C57BL/6 or SJL/J mice were injected subcutaneously with 100 µg of myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide (MEVG-WYSFSRVVHLRNGK) or Myelin proteolipid protein (PLP) 139–151 (HSLGKWLGHPDKF) emulsified with complete Freund’s adjuvant on day 0 and intravenous injection of 400 ng of pertussis toxin (List Biological Laboratories, Campbell, CA, USA) on days 0 and 2.

**Statistical analysis**

Data are presented as means ± SEM and are representative of at least three independent experiments. The statistical significance of differences between groups was calculated with a two-tailed Student’s t-test. Differences were considered significant for P < 0.05 (*) or 0.01 (**).

**Results**

**Expression of Npnt and α8 integrin in normal tissues**

We first examined the expression level of human and mouse Npnt (Fig. 1A) and α8 integrin (Fig. 1B) in healthy human and mouse tissues using real-time PCR. Subsequently, we found both Npnt and α8 integrin were highly expressed in the spleen; thus, we hypothesized that the interaction between Npnt and α8 integrin may be involved in immunological diseases.

**Establishing a sandwich ELISA system for Npnt**

To analyze the expression level of Npnt in an autoimmune mouse model, we sought to establish an Npnt sandwich ELISA system. For ELISA construction, two antibodies against Npnt were generated, Npnt3 rabbit polyclonal antibody and 20D1 monoclonal antibody.

---

**Fig. 1.** Expression of Npnt and α8 integrin in human and mouse tissues. Npnt (A) and α8 integrin (B) expression in healthy tissues were evaluated by real-time PCR. Data are representative of three or more independent experiments with similar results. Data are presented as means ± SEM.
For characterization of these antibodies, we purified full length of Npnt, EGF-like repeats, linker segment, MAM domain (Fig. 2A). Both antibodies were capable of detecting mouse and human Npnt (Fig. 2B). Notably, the molecular weight of human Npnt is higher than mouse because human Npnt is fused with a SUMO tag (approximate molecular weight of 20 kDa). A link truncated variant showed higher and broader bands than the expected size (approximately 28 kDa) as reported previously [22]. Anti-Npnt3 antibody recognized the MAM domain as predicted, whereas the 20D1 Ab did not react with a panel of Npnt truncated variants, suggesting that 20D1a Ab recognizes the Npnt conformation (Fig. 2B).

We developed an ELISA combination using Npnt3 as a coating antibody and 20D1 as a detecting antibody (Fig. 2C). The standard curve of the ELISA system exhibited a linear shape ranging from 0.078 to 5.0 ng·mL⁻¹ calculated with mouse Npnt (R&D) protein (Fig. 2C). To analyze the specificity of the ELISA, Npnt mRNA expression in various human and mouse cell lines was explored by RT–PCR. Human or mouse cell lines were left or right panel, respectively. (E) Detection of Npnt in supernatants from cell lines used in (C). Data are representative of three or more independent experiments with similar results. Data are presented as means ± SEM.

**Fig. 2.** Establishing the sandwich ELISA system for Npnt. (A) Schematic representation of Npnt and its truncated variants. Cell binding sequences (RGD sequences) in the linker segment and the epitope in the MAM domain of anti-Npnt3 antibody are indicated. (B) Specificity of Npnt3 and 20D1a antibodies by western blotting. (C) Diagram (top panel) and standard curve (lower panel) of the ELISA. Recombinant mNpnt (R&D) protein was used as the standard. (D) Expression of Npnt in cell lines by RT–PCR. Human or mouse cell lines were left or right panel, respectively. (E) Detection of Npnt in supernatants from cell lines used in (C). Data are representative of three or more independent experiments with similar results. Data are presented as means ± SEM.

**Elevated expression of Npnt in autoimmune diseases**

The antigenic peptide of anti-Npnt3 antibody is a common sequence shared by humans, mice, and rats, and the 20D1a antibody recognizes both human and...
mouse Npnt. Therefore, we assayed Npnt values in healthy mouse, human, and rat plasma samples. We found that the Npnt system can be used for quantification of mouse and human Npnt values with Npnt (R&D) protein as the standard. We next evaluated Npnt expression in urine since Npnt is highly expressed in kidneys. Significant expression of Npnt in human urine, but not mouse urine, was detected (Fig. 3A). Next, we tested Npnt levels in plasma samples from autoimmune mouse models, specifically ConA-hepatitis, CAIA, and EAE models. We found that Npnt levels in all of the inflammatory models we tested were significantly elevated (Fig. 3B).

**Involvement of α8β1 integrin-binding region of Npnt in inflammatory arthritis**

The RGD motif and LFEIFEIER sequence in Npnt are required for binding to α8β1 integrin, which is the physiological receptor for Npnt. To assess the importance of the α8β1 integrin-binding region within murine Npnt, we prepared the anti-Npnt-FD antibody that recognizes the PQKPRGDVFIIPQPTNDLFEIFEIER motif used as the antigen. We first examined the specificity of the anti-Npnt-FD antibody by direct ELISA, western blotting, or cell adhesion test. We also asked whether Npnt-FD antibody cross-reacts with fibronectin or GRGDS peptide since RGD motif found in many ECM molecules is exist in antigen peptide. The anti-Npnt-FD antibody recognized mouse Npnt protein, but not RGD motif-containing ECM, fibronectin or GRGDS peptide by direct ELISA (Fig. 4A), and detected mouse Npnt, human Npnt, and the Linker segment, which contains the antigen region of the anti-Npnt-FD antibody, by western blotting (Fig. 4B). To examine the functional specificity, cell adhesion assays were performed. Anti-Npnt-FD antibody partially inhibited cellular adhesion to mouse
and human Npnt, whereas it completely inhibited the adhesion of the α8β1 integrin-binding region, suggesting that an alternative Npnt exists (Fig. 4C). Anti-Npnt-FD antibody did not show any inhibitory activity toward fibronectin or vitronectin (Fig. 4D). These results indicate that anti-Npnt-FD antibody specifically recognizes and functionally inhibits the interaction of the α8β1 integrin-binding region of Npnt with its receptor.

An antibody against OPN, which is one of the α8β1 integrin ligands, inhibits an exacerbation of CAIA; thus, we assessed the function of the anti-Npnt-FD antibody in the CAIA model [23]. In the CAIA model, on day 6 the Npnt mRNA in arthritic joints was elevated. Furthermore, synovial fibroblasts and synovial macrophages, which are the main cellular components in arthritic synovia and important players in the joint pathology of rheumatoid arthritis...
Nephronectin is involved in CAIA

S. Kon et al.

Fig. 5. Npnt neutralization by anti-Npnt-FD antibody ameliorates CAIA. (A) Protocol for CAIA with anti-Npnt-FD antibody treatment. The antibody was administered to BALB/c mice on days −4 and 0 relative to LPS injection during CAIA induction. (B) Npnt expression in arthritic joints on day 6, synovial fibroblasts, or synovial macrophages were evaluated by real-time PCR. *P < 0.05, **P < 0.01, wild-type versus CAIA (Student’s t-test). (C) Arthritis scores of arthritic mice treated with control antibody (rabbit IgG) or an anti-Npnt-FD antibody at the indicated time points (n = 5 per group). *P < 0.05, **P < 0.01, anti-Npnt-FD antibody versus control Ig (Student’s t-test). Data are presented as means ± SEM. (D) Representative images of the forepaw and hindpaw on day 7 are shown. (E–G) Representative histology of normal joints and arthritic joints on day 14 from mice treated with control antibody or anti-Npnt-FD antibody. Sections were stained with HE (E, G) or Safranin-O (F). Magnified views of the boxed areas a and b are shown in F and G, respectively. Scale bar = 2 mm (E), 200 μm (F and G). Data are representative of three or more independent experiments with similar results.

(RA) [24, 25], were elevated (Fig. 5B). Treatment with the anti-Npnt-FD antibody on days −3 and 0 led to the delay of clinical onset of arthritis, and the severity of arthritis was significantly attenuated (Figure 5C). The gross appearance of arthritic joint treated with anti-Npnt-FD antibody on day 7 is shown in Fig. 5D. Finally, we evaluated the effect of anti-Npnt-FD antibody treatment on joint histology on day 14 after the LPS injection. In concert with the clinical score, histological analysis demonstrated marked differences. Cartilage destruction evaluated by Safranin-O staining was faint in the arthritic joints of control mice. In contrast, the staining was partially rescued in anti-Npnt-FD antibody-treated mice (Fig. 5F), indicating that the destruction of proteoglycans was partially prevented by the anti-Npnt-FD antibody. The proliferation of synovial cells, evaluated by HE staining, was detected in control antibody-treated mice; however, this feature of CAIA was clearly diminished following the administration of the anti-Npnt-FD antibody (Fig. 5G). These results strongly suggested that the α8β1 integrin-binding region of Npnt is involved in inflammatory arthritis.
Discussion

In the present study, we investigated the function of Npnt in autoimmune diseases as high levels of Npnt mRNA were found in the spleens of humans and mice. We developed a sandwich ELISA system for quantifying the protein level of Npnt in autoimmune diseases and found that Npnt in blood is increased in various autoimmune diseases. The results from ConA-hepatitis are consistent with previous reports that observed elevated Npnt mRNA [18].

For clarification of Npnt function in autoimmune diseases, we generated a neutralizing antibody against Npnt (anti-Npnt-FD antibody) by immunizing rabbits with the PQKPRGDVFIPRQPTNDLFEIFEIER peptide (Npnt-FD peptide), because the RGD motif and LFEIFEIER sequence in Npnt plays a critical role in the binding to its physiological receptor, α8β1 integrin [22]. Anti-Npnt-FD antibody partially inhibits cell adhesion of full-length mouse and human Npnt to NIH3T3 cells, which express α8β1 integrin [26]. This suggests that Npnt has other receptors on NIH3T3 cells. In fact, it has been reported that the MAM domain in Npnt binds to heparan sulfate proteoglycan and EGF-like repeats domain and activates the EGF receptor [13,27]. Therefore, anti-Npnt-FD antibody specifically inhibits the interaction between Npnt and receptors bound to Npnt-FD peptide such as α8β1 integrin.

Previously, we reported that neutralizing antibodies for osteopontin, one of the ligands of α8β1 integrin, inhibits the development of inflammatory arthritis in the CAIA model. Therefore, we analyzed the function of Npnt in CAIA and determined that anti-Npnt-FD antibody attenuates the severity of arthritis. We also found higher expression of Npnt in arthritic joints than in control mice. In RA joints, proliferating fibroblasts and macrophages are clearly seen. These cells are thought to cause an exacerbation of RA by secretion of various pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α or interleukin (IL)-1β. In this study, Npnt expression in synovial fibroblasts and macrophages from CAIA was also increased, suggesting a critical involvement of the PQKPRGDVFIPRQPTNDLFEIFEIER sequence of Npnt and its receptor(s) in the development of inflammatory arthritis and, perhaps, the combination of Npnt and these cytokines have a synergistic effect on the severity of inflammation.

The α8β1 integrin, which is part of the RGD-recognizing integrin family, is prominently expressed in smooth muscle and has a defined in vivo role in kidney development and liver and lung fibrosis [10,11,28,29]. In this study, α8β1 integrin is highly expressed in human and mouse spleen, suggesting that α8β1 integrin has any important role in immune responses. It is conceivable that the binding of Npnt to α8β1 integrin is involved in α8β1 integrin, but we cannot exclude the possibility that other RGD-recognizing integrins, such as αvβ3 integrin, are the Npnt receptor during inflammatory arthritis. Further research is required to understand how α8β1 integrin is involved in inflammatory arthritis.

In conclusion, we found that Npnt is highly expressed in the spleen and upregulated in blood from various autoimmune mouse models. Furthermore, we provide evidence for a potential role of the α8β1 integrin-binding region of Npnt in the pathogenesis of inflammatory arthritis. Further studies will be directed at understanding the mechanism by which Npnt and its interactions with integrins affect autoimmune diseases.

Acknowledgements

This study was supported by research grants from JSPS KAKENHI Grant Numbers 16K08221 and 19K07492. Japan Rheumatism Foundation, the SUHARA Memorial Foundation, the FUGAKU TRUST for Medical Research, academic support from Pfizer, Chugai, Astellas, and Eli Lilly to SK. We thank S. J. Win, PhD, from Edanz Group for editing a draft of this manuscript.

Conflict of interest

SK and MH declare no conflicts of interest associated with this manuscript. KI, MM, and TS are employees of the Immuno-Biological Laboratories Co., Ltd.

Author contributions

SK conceived and carried out experiments and wrote the manuscript; MH performed experiments; KI, MM, and TS generated anti-Npnt antibody and established the Npnt ELISA system; SK and TS supervised the study. All authors read and approved the final manuscript.

References

1. Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326, 1216–1219.
2. Giancotti FG and Ruoslahti E (1999) Integrin signaling. Science 285, 1028–1032.
Nephronectin is involved in CAIA
S. Kon et al.

3 Hynes RO (2014) Stretching the boundaries of extracellular matrix research. Nat Rev Mol Cell Biol 15, 761–763.
4 Hynes RO (1987) Integrins: a family of cell surface receptors. Cell 48, 549–554.
5 Hasegawa M, Yoshida T and Sudo A (2018) Role of tenascin-C in articular cartilage. Mod Rheumatol 28, 215–220.
6 Schultz C (2019) Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis. Br J Pharmacol 176, 26–37.
7 Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, Okazaki I, Seki N, Fuji T and Uede T (2003) Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112, 181–188.
8 Kon S, Nakayama Y, Matsumoto N, Ito K, Kanayama M, Kimura C, Kouro H, Ashtomi D, Matsuda T and Uede T (2014) A novel cryptic binding motif, LRSSKSRSFQVSDEQY, in the C-terminal fragment of MMP-3/7-cleaved osteopontin as a novel ligand for alpha9beta1 integrin is involved in the anti-type II collagen antibody-induced arthritis. PLoS ONE 9, e116210.
9 Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T et al. (2004) Osteopontin as a mediator of NKT cell metabolism and chronic inflammation in rheumatoid arthritis. J Immunol 173, 539–550.
10 Brandenberger R, Schmidt A, Linton J, Wang D, Backus C, Denda S, Muller U and Reichardt LF (2001) Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin alpha9beta1 in the embryonic kidney. J Cell Biol 154, 447–458.
11 Fujiwara H, Ferreira M, Donati G, Marciano DK, Linton JM, Sato Y, Hartner A, Sekiguchi K, Reichardt LF and Watt FM (2011) The basement membrane of hair follicle stem cells is a muscle cell niche. Cell 144, 577–589.
12 Miner JH (2001) Mystery solved: discovery of a novel integrin ligand in the developing kidney. J Cell Biol 154, 257–259.
13 Sato Y, Shimono C, Li S, Nakano I, Norioka N, Sugiuira N, Kimata K, Yamada M and Sekiguchi K (2013) Nephronectin binds to heparan sulfate proteoglycans via its MAM domain. Matrix Biol 32, 188–195.
14 Cheng CW, Ka SM, Yang SM, Shui HA, Hung YW, Ho PC, Su YC and Chen A (2008) Nephronectin expression in nephrotic acute tubular necrosis. Nephrol Dial Transplant 23, 101–109.
15 Muller-Deile J, Dannenberg J, Schroder P, Lin MH, Miner JH, Chen R, Brasen JH, Thum T, Nystrom J, Staggs LB et al. (2017) Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases. Kidney Int 92, 836–849.
16 Nakatani S, Ishimura E, Mori K, Fukumoto S, Yamano S, Wei M, Emoto M, Wamibuchi H and Inaba M (2012) Nephronectin expression in glomeruli of renal biopsy specimens from various kidney diseases: nephronectin is expressed in the mesangial matrix expansion of diabetic nephropathy. Nephron Clin Pract 122, 114–121.
17 Kashani K and Kellum JA (2015) Novel biomarkers indicating repair or progression after acute kidney injury. Curr Opin Nephrol Hypertens 24, 21–27.
18 Inagaki FF, Tanaka M, Inagaki NF, Yagai T, Sato Y, Sekiguchi K, Oyaizu N, Kokudo N and Miyajima A (2013) Nephronectin is upregulated in acute and chronic hepatitis and aggravates liver injury by recruiting CD4 positive cells. Biochem Biophys Res Commun 430, 751–756.
19 Dilmac S, Erin N, Demir N and Tamirigo G (2018) Nephronectin is decreased in metastatic breast carcinoma and related to metastatic organs. Pathol Oncol Res 24, 679–688.
20 Steigedal TS, Toraskar J, Redvers RP, Valla M, Magnussen SN, Boftin AM, Opdahl S, Lundgren S, Eckhardt BL, Lamar JM et al. (2018) Nephronectin is correlated with poor prognosis in breast cancer and promotes metastasis via its integrin-binding motifs. Neoplasia 20, 387–400.
21 Wang D, Zhao C, Gao L, Wang Y, Gao X, Tang L, Zhang K, Li Z, Han J and Xiao J (2018) NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche. J Bone Oncol 13, 91–96.
22 Sato Y, Uemura T, Morimitsu K, Sato-Nishiiuchi R, Manabe R, Takagi J, Yamada M and Sekiguchi K (2009) Molecular basis of the recognition of nephronectin by integrin alpha9beta1. J Biol Chem 284, 14524–14536.
23 Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N et al. (2009) Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 182, 8015–8025.
24 Muller-Ladner U, Ospelt C, Gay S, Distler O and Pap T (2007) Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts, Arthritis Res Ther 9, 223.
25 Falconer J, Murphy AN, Young SP, Clark AR, Tiziani S, Guma M and Buckley CD (2018) Review: synovial cell metabolism and chronic inflammation in rheumatoid arthritis. Arthritis Rheumatol 70, 984–999.
26 Denda S, Reichardt LF and Muller U (1998) Identification of osteopontin as a novel ligand for the
integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. *Mol Biol Cell* **9**, 1425–1435.

27 Kahai S, Lee SC, Seth A and Yang BB (2010) Nephronectin promotes osteoblast differentiation via the epidermal growth factor-like repeats. *FEBS Lett* **584**, 233–238.

28 Hung CF, Wilson CL, Chow YH and Schnapp LM (2018) Role of integrin alpha8 in murine model of lung fibrosis. *PLoS ONE* **13**, e0197937.

29 Levine D, Rockey DC, Milner TA, Breuss JM, Fallon JT and Schnapp LM (2000) Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. *Am J Pathol* **156**, 1927–1935.